Big Pharma just rewrote the rulebook in the obesity-treatment race. Pfizer has won the bidding for Metsera after a showdown with Novo Nordisk.

Dan Koh and Emaad Akhtar unpack how this US$10 billion move signals a pivot into GLP-1 drugs, why Novo walked away and what it all means for investors tracking the next trillion-dollar health-tech frontier.

Big Pharma just rewrote the rulebook in the obesity-treatment race. Pfizer has won the bidding for Metsera after a showdown with Novo Nordisk.
Dan Koh and Emaad Akhtar unpack how this US$10 billion move signals a pivot into GLP-1 drugs, why Novo walked away and what it all means for investors tracking the next trillion-dollar health-tech frontier.

Insightful discussions on the latest market events and the top companies to watch.

Get a head start to your work day with Ryan Huang, Emaad Akhtar and Audrey Siek from 6am to 9am. 

Listen to insightful discussions on the stories and issues that matter the most to you and be apprised of the markets and the companies to watch.

Get a head start to your work day with Ryan Huang, Emaad Akhtar and Audrey Siek from 6am to 9am. 
Listen to insightful discussions on the stories and issues that matter the most to you and be apprised of the markets and the companies to watch.

Breakfast with Ryan Huang, Emaad Akhtar and Audrey Siek

Get a head start on your workday with Ryan Huang, Emaad Akhtar and Audrey Siek from 6 am to 9 am. 

Listen to insightful discussions on the stories and issues that matter the most to you and be apprised of the markets and the companies to watch.

Get a head start on your workday with Ryan Huang, Emaad Akhtar and Audrey Siek from 6 am to 9 am. 
Listen to insightful discussions on the stories and issues that matter the most to you and be apprised of the markets and the companies to watch.

Advertisement